JP7646542B2 - 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 - Google Patents

新規アンタゴニスト抗ｔｎｆｒ２抗体分子 Download PDF

Info

Publication number
JP7646542B2
JP7646542B2 JP2021523957A JP2021523957A JP7646542B2 JP 7646542 B2 JP7646542 B2 JP 7646542B2 JP 2021523957 A JP2021523957 A JP 2021523957A JP 2021523957 A JP2021523957 A JP 2021523957A JP 7646542 B2 JP7646542 B2 JP 7646542B2
Authority
JP
Japan
Prior art keywords
antibody molecule
antibody
tnfr2
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512905A (ja
JP2022512905A5 (enExample
Inventor
フレンデウス ビョルン
テイゲ イングリッド
モルテンソン リンダ
ホルムコビスト ペトラ
センリヒ モニカ
Original Assignee
バイオインベント インターナショナル アクティエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインベント インターナショナル アクティエボラーグ filed Critical バイオインベント インターナショナル アクティエボラーグ
Publication of JP2022512905A publication Critical patent/JP2022512905A/ja
Publication of JP2022512905A5 publication Critical patent/JP2022512905A5/ja
Priority to JP2024188854A priority Critical patent/JP2025022888A/ja
Application granted granted Critical
Publication of JP7646542B2 publication Critical patent/JP7646542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021523957A 2018-11-01 2019-11-01 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 Active JP7646542B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024188854A JP2025022888A (ja) 2018-11-01 2024-10-28 新規アンタゴニスト抗ｔｎｆｒ２抗体分子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18203993.3 2018-11-01
EP18203993 2018-11-01
PCT/EP2019/080004 WO2020089474A1 (en) 2018-11-01 2019-11-01 Novel antagonistic anti tnfr2 antibody molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024188854A Division JP2025022888A (ja) 2018-11-01 2024-10-28 新規アンタゴニスト抗ｔｎｆｒ２抗体分子

Publications (3)

Publication Number Publication Date
JP2022512905A JP2022512905A (ja) 2022-02-07
JP2022512905A5 JP2022512905A5 (enExample) 2022-10-26
JP7646542B2 true JP7646542B2 (ja) 2025-03-17

Family

ID=64109794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523957A Active JP7646542B2 (ja) 2018-11-01 2019-11-01 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
JP2024188854A Withdrawn JP2025022888A (ja) 2018-11-01 2024-10-28 新規アンタゴニスト抗ｔｎｆｒ２抗体分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024188854A Withdrawn JP2025022888A (ja) 2018-11-01 2024-10-28 新規アンタゴニスト抗ｔｎｆｒ２抗体分子

Country Status (11)

Country Link
US (2) US12441805B2 (enExample)
EP (1) EP3873936A1 (enExample)
JP (2) JP7646542B2 (enExample)
KR (1) KR20210087029A (enExample)
CN (3) CN118667024A (enExample)
AU (1) AU2019372184B2 (enExample)
BR (1) BR112021007995A2 (enExample)
CA (1) CA3117864A1 (enExample)
IL (1) IL282715B1 (enExample)
MX (1) MX2021005150A (enExample)
WO (1) WO2020089474A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210087466A (ko) * 2018-11-01 2021-07-12 바이오인벤트 인터내셔날 에이비 신규한 효능작용 항 tnfr2 항체 분자
JP7895285B2 (ja) * 2020-06-12 2026-07-27 ナンチン リーズ バイオラブス カンパニー，リミティド Ｔｎｆｒ２に結合する抗体およびその用途
US20240043551A1 (en) * 2020-12-11 2024-02-08 Adlai Nortye Biopharma Co., Ltd. Anti-tnfr2 antibody and application thereof
CN117425675A (zh) * 2020-12-31 2024-01-19 新石生物制药有限公司 Tnfr2抗体及其用途
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス， リミテッド Ｔｎｆｒ２に対する抗体およびそれの使用
EP4286411A4 (en) * 2021-01-29 2025-06-25 Shandong Simcere Biopharmaceutical Co., Ltd. Humanized antibody against tnfr2 and use thereof
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CN116333123B (zh) * 2021-12-22 2026-08-07 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途
CN119591711B (zh) * 2024-11-12 2026-01-13 澳门大学 一种抑制性tnfr2单域抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509009A (ja) 2013-02-07 2016-03-24 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP2017043608A (ja) 2011-06-30 2017-03-02 中外製薬株式会社 ヘテロ二量化ポリペプチド
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
JP2017522025A (ja) 2014-07-16 2017-08-10 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
KR20070084069A (ko) 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
JP6869987B2 (ja) * 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
US11359027B2 (en) * 2016-06-22 2022-06-14 Universite Paris Est Creteil Val De Marne Prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017043608A (ja) 2011-06-30 2017-03-02 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP2016509009A (ja) 2013-02-07 2016-03-24 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
JP2017522025A (ja) 2014-07-16 2017-08-10 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2017083525A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TORREY, H., et al.，"Targeting TNFR2 with antagonisticc antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs."，SCIENCE SINGALING，2017年01月17日，Vol.10, No.462，eaaf8608(pp.1-12)，DOI: 10.1126/scisignal.aaf8608

Also Published As

Publication number Publication date
JP2022512905A (ja) 2022-02-07
IL282715A (en) 2021-06-30
CN118702818A (zh) 2024-09-27
US12441805B2 (en) 2025-10-14
MX2021005150A (es) 2021-07-15
US20220073634A1 (en) 2022-03-10
US20250388690A1 (en) 2025-12-25
CN112955469B (zh) 2024-08-06
EP3873936A1 (en) 2021-09-08
IL282715B1 (en) 2026-08-01
AU2019372184A1 (en) 2021-05-27
CN112955469A (zh) 2021-06-11
WO2020089474A8 (en) 2021-06-24
AU2019372184B2 (en) 2026-06-25
CN118667024A (zh) 2024-09-20
KR20210087029A (ko) 2021-07-09
JP2025022888A (ja) 2025-02-14
BR112021007995A2 (pt) 2021-08-10
WO2020089474A1 (en) 2020-05-07
CA3117864A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7664833B2 (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
US20250388690A1 (en) Novel antagonistic anti-tnfr2 antibodies
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
CN110869388A (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
JP2022513432A (ja) 免疫細胞活性化のための二重特異性抗体
KR20200038530A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
US20240018248A1 (en) An ltbr agonist in combination therapy against cancer
CN111683969A (zh) 抗体的新型组合和用途
JP2025157305A (ja) 特定の患者のがんを治療するための抗体の組み合わせ
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
HK40109442A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
CN115368457A (zh) 抗tigit抗体及其用途
HK40128816A (zh) 新颖激动性抗tnfr2抗体分子
HK40050308B (en) Novel antagonistic anti tnfr2 antibody molecules
HK40129120A (en) Novel agonistic anti tnfr2 antibody molecules
HK40050308A (en) Novel antagonistic anti tnfr2 antibody molecules
RU2816531C2 (ru) Комбинации антител для лечения рака у конкретных пациентов
RU2840049C9 (ru) Новые молекулы агонистических анти-tnfr2 антител
RU2840049C2 (ru) Новые молекулы агонистических анти-tnfr2 антител

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250305

R150 Certificate of patent or registration of utility model

Ref document number: 7646542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150